The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...

Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...